Insilico deepens Tenacia CNS partnership in $94.75M AI deal
CURRENT BRIEF VERSION: Insilico Medicine and Tenacia Biotechnology said on March 26, 2026, that they’re expanding their central nervous system drug discovery alliance, adding a second AI-driven program with a total potential value of up to $94.75 million. The companies said the original collaboration, launched in March 2025, used Insilico’s Pharma.AI platform alongside Tenacia’s CNS expertise and proprietary data to design small-molecule inhibitors with blood-brain barrier permeability, and that progress in that first program prompted the expansion. Under the new agreement, the partners plan to advance another candidate for difficult neurological diseases through preclinical candidate stage, with Insilico eligible for near-term and milestone payments. (prnewswire.com)
Why it matters: For veterinary professionals, this isn’t a companion animal deal, but it’s another signal that AI-enabled CNS discovery is moving from platform promise to repeat business. Neurology remains one of the hardest areas in both human and animal health because brain penetration, target selection, and late-stage attrition are persistent barriers. A collaboration expanding after one year suggests partners are seeing enough technical traction to fund another program, which could reinforce broader industry confidence in AI-assisted design for neurologic disease. Insilico has also been widening its partnership footprint, including other CNS deals and a major Eli Lilly collaboration that gave Lilly exclusive global rights to develop, manufacture, and commercialize select preclinical oral candidates discovered with Pharma.AI across multiple therapeutic areas; that deal included $115 million upfront and a total potential value of up to $2.75 billion plus tiered royalties. Together, those agreements underscore how quickly AI drug discovery is becoming embedded in biopharma strategy. (prnewswire.com)
What to watch: Watch for disclosure of the target, any preclinical candidate nomination from the first or second Tenacia program, and whether Insilico’s growing run of AI-partnering deals translates into clinical data that validates the model. (prnewswire.com)